Efficacia e tollerabilita del topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico

R. Canger; G. Avanzini; A. Tartara; C. Durisotti; L. Guidolin; S. Binelli; L. Canafoglia; I. Sartori; P. Garofalo; M. Di Fazio; C. Cicogna; D. Bertelletti; E. Perucca

Efficacia e tollerabilita del topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico

Translated title of the contribution: Topiramate efficacy and tolerability as add-on therapy: Interim analysis of an open multicenter study

R. Canger, G. Avanzini, A. Tartara, C. Durisotti, L. Guidolin, S. Binelli, L. Canafoglia, I. Sartori, P. Garofalo, M. Di Fazio, C. Cicogna, D. Bertelletti, E. Perucca

Research output: Contribution to journal › Article › peer-review

Abstract

The long-term open-label study described is the Italian experience as a part of an ongoing international research aimed at evaluating topiramate's efficacy and tolerability in patients with uncontrolled epilepsy of any seizure type. 67 patients from 4 Italian centers were studied. The results indicate topiramate as an efficacious drug in a difficult and disomogeneous population of particulariy severe refractory patients. Medium dose used in the study is 300 mg topiramate per day; 8% of the patients was seizure-free; tolerability was generally good.

Translated title of the contribution	Topiramate efficacy and tolerability as add-on therapy: Interim analysis of an open multicenter study
Original language	Italian
Pages (from-to)	251-253
Number of pages	3
Journal	Bollettino - Lega Italiana contro l'Epilessia
Issue number	95-96
Publication status	Published - 1996

ASJC Scopus subject areas

Clinical Neurology

Cite this

@article{8a5dc8a5899c43cf91469a2dca565108,

title = "Efficacia e tollerabilita del topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico",

abstract = "The long-term open-label study described is the Italian experience as a part of an ongoing international research aimed at evaluating topiramate's efficacy and tolerability in patients with uncontrolled epilepsy of any seizure type. 67 patients from 4 Italian centers were studied. The results indicate topiramate as an efficacious drug in a difficult and disomogeneous population of particulariy severe refractory patients. Medium dose used in the study is 300 mg topiramate per day; 8% of the patients was seizure-free; tolerability was generally good.",

keywords = "Add-on therapy, Longterm open-label study, Topiramate",

author = "R. Canger and G. Avanzini and A. Tartara and C. Durisotti and L. Guidolin and S. Binelli and L. Canafoglia and I. Sartori and P. Garofalo and {Di Fazio}, M. and C. Cicogna and D. Bertelletti and E. Perucca",

year = "1996",

language = "Italian",

pages = "251--253",

journal = "Bollettino - Lega Italiana contro l'Epilessia",

issn = "0394-560X",

publisher = "Lega Italiana contro l'Epilessia",

number = "95-96",

}

TY - JOUR

T1 - Efficacia e tollerabilita del topiramato in terapia add-on

T2 - Analisi ad interim di uno studio aperto policentrico

AU - Canger, R.

AU - Avanzini, G.

AU - Tartara, A.

AU - Durisotti, C.

AU - Guidolin, L.

AU - Binelli, S.

AU - Canafoglia, L.

AU - Sartori, I.

AU - Garofalo, P.

AU - Di Fazio, M.

AU - Cicogna, C.

AU - Bertelletti, D.

AU - Perucca, E.

PY - 1996

Y1 - 1996

N2 - The long-term open-label study described is the Italian experience as a part of an ongoing international research aimed at evaluating topiramate's efficacy and tolerability in patients with uncontrolled epilepsy of any seizure type. 67 patients from 4 Italian centers were studied. The results indicate topiramate as an efficacious drug in a difficult and disomogeneous population of particulariy severe refractory patients. Medium dose used in the study is 300 mg topiramate per day; 8% of the patients was seizure-free; tolerability was generally good.

AB - The long-term open-label study described is the Italian experience as a part of an ongoing international research aimed at evaluating topiramate's efficacy and tolerability in patients with uncontrolled epilepsy of any seizure type. 67 patients from 4 Italian centers were studied. The results indicate topiramate as an efficacious drug in a difficult and disomogeneous population of particulariy severe refractory patients. Medium dose used in the study is 300 mg topiramate per day; 8% of the patients was seizure-free; tolerability was generally good.

KW - Add-on therapy

KW - Longterm open-label study

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=0030410915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030410915&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0030410915

SP - 251

EP - 253

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 95-96

ER -

Efficacia e tollerabilita del topiramato in terapia add-on: Analisi ad interim di uno studio aperto policentrico

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this